Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06129409 · ClinicalTrials.gov registry record · Phase 1
Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease
A Phase 1 study of Cardiovascular Diseases, sponsored by NodThera Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
- 2
- Study locations
NCT06129409: Completed Phase 1 study of Cardiovascular Diseases, sponsored by NodThera Limited.
NCT06129409 is a Phase 1 study of Cardiovascular Diseases that has completed, run by NodThera Limited. The registered enrollment target is 67 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06129409, a Phase 1 study of Cardiovascular Diseases, has completed, sponsored by NodThera Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease. Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be discharged on Day 30. The trial will include a 7-day out-patient safety follow-up period following the last dose of study treatment. For the first approximately 20 participants effect of food will be evaluated on the Pharmacokinetics of NT-0796. MRI's will be conducted in a subset of participants.
Primary Outcome
Evaluate the effects of NT-0796 on inflammation.
Conditions Studied
Interventions
- DRUG NT-0796
Study Locations (2)
Florida
- Investigative Site - Miami
Texas
- Investigative Site - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2023-10-10 |
| Est. Completion | 2024-04-15 |
| Phase | Phase 1 |
What the finished NCT06129409 record still lists
NCT06129409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which NT-0796 is the first listed.
NCT06129409 reports a single indexed study location in Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06129409 about?
NCT06129409 is a clinical study titled "Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease". This trial is a Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled Study to Assess the Effect of NT-0796 on Inflammation in Obese Participants at Risk of Cardiovascular Disease. Participants will be admitted to an in-patient Clinical Research Unit on Day -1 and will be discharged on Day 30...
What is the current status of trial NCT06129409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2023-10-10. Estimated completion is 2024-04-15.
What conditions does trial NCT06129409 study?
This clinical trial studies the following conditions: Cardiovascular Diseases.
What interventions are being tested in trial NCT06129409?
The interventions under investigation include: NT-0796 (DRUG).
Who is sponsoring clinical trial NCT06129409?
This trial is sponsored by NodThera Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06129409 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06129409's enrollment target sits among peer trials
67 217th of 300 higher than 84 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RECRUITING · Phase 1
-
Prevention of Progression of Prediabetes, Obesity and CV Risk
RECRUITING · Phase 1
-
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
RECRUITING · Phase 1
-
AB-1002 in Patients With Class III Heart Failure
ACTIVE NOT RECRUITING · Phase 1
-
MRI-Guided Balloon Angioplasty to Treat Blood Flow Blockage in the Legs
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI